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Background: Reviews suggest that the ADO score is the most discriminatory prognostic
score for predicting mortality among chronic obstructive pulmonary disease (COPD)
patients, but a full evaluation and external validation within primary care settings is critical
before implementation.
Objectives: To validate the ADO score in prevalent and screen-detected primary care
COPD cases at 3 years and at shorter time periods.
Patients and methods: One thousand eight hundred and ninety-two COPD cases were
recruited between 2012 and 2014 from 71 United Kingdom general practices as part of the
Birmingham COPD Cohort study. Cases were either on the practice COPD register or screen-
detected. We validated the ADO score for predicting 3-year mortality with 1-year and 2-year
mortality as secondary endpoints using discrimination (area-under-the-curve (AUC)) and
calibration plots.
Results: One hundred and ﬁfty-four deaths occurred within 3 years. The ADO score was
discriminatory for predicting 3-year mortality (AUC= 0.74; 95% CI: 0.69–0.79). Similar
performance was found for 1- (AUC= 0.73; 0.66–0.80) and 2-year mortality (0.72; 0.67–
0.76). The ADO score showed reasonable calibration for predicting 3-year mortality (cali-
bration slope 0.95; 0.70–1.19) but over-predicted in cases with higher predicted risks of
mortality at 1 (0.79; 0.45–1.13) and 2-year (0.79; 0.57–1.01) mortality.
Discussion: The ADO score showed promising discrimination in predicting 3-year mortality
in a primary care population including screen-detected cases. It may need to be recalibrated if
it is used to provide risk predictions for 1- or 2-year mortality since, in these time-periods,
over-prediction was evident, especially in cases with higher predicted mortality risks.
Keywords: pulmonary disease, chronic obstructive, mortality, prognosis, validation studies
Plain Language Summary
Prediction models are tools that can be used to provide estimates of likely outcomes, such as
death, over a speciﬁed time period in individual patients. This information can then be used
to inform treatment decisions. For example, the intensity of treatment (or monitoring) may be
increased for those with higher individual risks. These tools are usually developed using data
from one group of people. However, because other groups of people may have different
characteristics, the accuracy of the tool needs to be checked in these other groups. The ADO
(age, dyspnoea (i.e. breathlessness), and obstructed airways) score was developed to predict
death within 3 years in people with COPD. Our aim was to check whether the ADO score is
accurate in predicting the risk of death in a group of people with COPD identiﬁed in general
practices in the UK. We also wanted to determine whether it was accurate for predicting the
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risk of death at time periods shorter than 3 years. Previous
studies have shown that the ADO score distinguishes well
between likelihood of being dead or alive (i.e. the discrimination
of a model). In our sample of people with newly diagnosed and
existing COPD in primary care, we conﬁrmed these results.
However, previous studies have not properly assessed the degree
of agreement between the expected and observed individual risk
of death (i.e. the calibration of a model). It is essential to report
calibration in prognostic models because it tells you how accu-
rate mortality predictions are likely to be for individual with a
particular disease. We found that the ADO score over-predicts
individual risk of death for periods <3 years. Unless adjusted,
this reduces its usefulness for clinical decision-making. In addi-
tion, this has implications for other COPD prognostic scores that
have been tested and used at shorter time periods than they were
developed for.
Introduction
Chronic obstructive pulmonary disease (COPD) is the
third leading cause of mortality worldwide.1,2 Prognostic
scores to predict mortality risk in people with COPD are
useful in order to assess disease severity, deﬁne interven-
tion options, and facilitate consultations with patients
about their prognosis.3 Knowledge of the risk of mortality
also allows the beneﬁts of treatments for COPD to be
weighed against potential harms, such as side effects,
costs, and inconvenience2 in order to enable informed
clinical decision-making. The extent of airﬂow obstruc-
tion, usually assessed by forced expiratory volume in the
ﬁrst second (FEV1), has long been recognised as an impor-
tant measure of prognosis and is used for disease staging.2
However, the complex and multifaceted nature of COPD4,5
has led to the identiﬁcation of other important predictors
of mortality and the recognition that combining these in
multicomponent indices6–10 improves prognostic ability.
However, before implementation in clinical practice, it is
important to evaluate the predictive ability of the prognos-
tic index in different populations.3 There are two important
aspects to such evaluation, including assessment of how
well the index can differentiate between those who die and
those who remain alive (i.e. discrimination) and the extent
of agreement between predicted and observed mortality
(i.e. calibration). The latter is particularly important for
prognostication.11
Amongst prognostic indices, the ADO (age, dyspnoea,
airﬂow obstruction) score has wide applicability as it is
made up of only three easily measured components,9 over-
coming the limitation of many other indices.12 The origi-
nal ADO score was developed in 20099 to predict 3-year
mortality in patients with moderate-to-severe COPD from
secondary care and was updated in 2012 in an interna-
tional cohort from a variety of healthcare settings to
improve its generalisability.13 The updated ADO has
been externally validated several times.13–16 However,
only two validation studies were in primary care
populations,14,16 where most people with COPD are
cared for.17 In one of these studies, calibration was not
assessed.14 The other study only considered 2-year mor-
tality as the outcome and adjusted the intercept of the
ADO score.16 A further two studies used populations
across primary, secondary and tertiary settings.13,15
However, no analyses were undertaken to assess the dif-
ferential performance of the ADO score in each setting.
Our aim was to validate the updated ADO score in
COPD cases from a large primary care research cohort (the
Birmingham COPD cohort) which included both pre-
viously and newly diagnosed cases and where dyspnoea
and lung function were measured under standardized
conditions.
Methods
This paper was written in accordance with the Transparent
Reporting of a multivariable prediction model for Individual
Prognosis Or Diagnosis statement.18
Design
External validation study of a published prognostic score.
Source And Study Population
The characteristics of the Birmingham COPD cohort,
which is part of the Birmingham Lung Improvement
Studies (BLISS), have been summarized in a previous
publication.19 Brieﬂy, COPD cases were recruited from
71 UK general practices across the West Midlands,
United Kingdom. For this analysis, cohort cases with
diagnosed COPD (aged 40 and over) on practice Quality
and Outcomes Framework COPD registers (i.e. prevalent
cases) and those with newly detected COPD identiﬁed
through a case-ﬁnding trial (i.e. incident cases were
screen-detected)20 were included. The deﬁnition of
COPD in incident cases was based on reporting of relevant
symptoms in those with airﬂow obstruction (forced expira-
tory volume in the ﬁrst second (FEV1)/forced vital capa-
city (FVC) <0.7 according to recommendations in UK
guidelines). Baseline assessments took place at cohort
entry from 31 May 2012 to 25 June 2014.
Keene et al Dovepress
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Exposure And Outcome Measurements
The ADO score (0–14) was computed from three variables
taken at baseline: age, dyspnoea (modiﬁed MRC score), and
obstruction (FEV1% predicted). Age was calculated from
patient-reported date of birth, and dyspnoea was assessed
by a questionnaire using the British Medical Research
Council guidelines.21 A researcher trained to international
standards to measure FEV1 administered the nddEasy One
Spirometer (ndd, Switzerland) before (max eight blows) and
after (max six blows) 400µg salbutamol, aiming for three
blows within 100 mL. FEV1 and FVC recording were con-
sidered useable if they met ATS acceptability criteria and
were within 200mL. The highest recording was then taken.19
Quality assurance was maintained using real-time quality
assessment, with over-reading of spirometry measurements.
FEV1% predicted was estimated using the Global Lung
Function Initiative equations.22
Linked mortality data were obtained through the Ofﬁce
of National Statistics for the period of recruitment until 31
March 2016 through NHS Digital.23 Other patient charac-
teristics including ethnicity, level of deprivation (using
Index of Multiple Deprivation derived from home post-
code), smoking status, quality of life, and medical history
(including self-reported comorbidities and previous
exacerbations) were obtained by patient self-report
through standardized questionnaires. Body mass index
(BMI derived from height and weight measurements) and
exercise capacity (using sit-to-stand test) were obtained by
trained researchers using standardised protocols at the
baseline visit.19
Patient Selection Criteria
The ADO score was developed for participants 40 years
and older. Missing baseline mMRC scores or FEV1%
predicted observations were imputed using multiple
imputation (MI) by chained equations so that all remain-
ing incident and prevalent cases (N= 1892) could be
included in the ﬁnal analyses (baseline tables show
data prior to imputation). Additional auxiliary variables
(cardiovascular disease history, cardiovascular disease
medication, chronic cough, chronic phlegm, ethnicity,
and gender) were used to aid the imputation. The num-
ber of imputed datasets used was based on the fraction
of missing data for all variables (11%, so 11 MI datasets
were used).24 Death data were complete for all cases
under the assumption that patients without a date of
death remained alive.
Analysis
Baseline characteristics were compared between preva-
lent and incident cases as well as between those who
died within 3 years of study entry compared to those
who did not. Chi-square and Student’s t-tests were used
for categorical and continuous variables, respectively.
The updated ADO score regression coefﬁcients and
intercept13 were used to compute the predicted probability
of 3-year mortality for each eligible cohort participant
(Supplementary Table 1). To assess discrimination, area-
under-the-curve (AUC) was estimated with a 95% conﬁ-
dence interval (95% CI) and plotted using AUC-ROC
plots.25 Calibration was assessed by comparing the pre-
dicted probability to the observed probability of mortality
and examined with a calibration plot and calibration slope
with 95% CI. Calibration plots (STATA function: pmcal-
plot) displayed observed risk by deciles of the predicted
risk and also examined risk at the individual level using
Locally Weighted Scatterplot Smoothing algorithms.26 An
estimate of the Calibration-in-the-large (CITL) was used to
indicate whether the predictions were systematically too
high or too low.26 As MI datasets were used, the AUC and
calibration slope were estimated in each individual MI
dataset, before Rubin’s rule was used to combine
estimates.27
A Kaplan–Meier plot was created according to ADO
score group (0 to 5, 6 and 7, 8 and 9, and 10 to 14). Scores
were grouped based on the number of patients. Separation
of Kaplan–Meier curves for ADO score groups indicates
better discriminative performance.
In secondary analyses (using the same discrimination
and calibration methods as above), we evaluated the
ability of the ADO index to predict mortality at 1 and
2 years. The period end dates for each case were 1, 2,
and 3 years after study entry. If the end date for the
period fell after the 31 March 2016, then the case was
excluded from that period. Period exclusions were
made regardless of whether and at what time cases
died to ensure that dead and alive cases were treated
the same. However, a sensitivity analysis was performed
by re-introducing cases that died within a certain period
despite a period end date that fell after the 31 March
2016. Two additional sensitivity analyses were con-
ducted: 1) We estimated the discrimination and calibra-
tion estimates for prevalent cases alone and 2) for
complete cases (non-missing obstruction and dyspnoea).
Prevalent cases were studied alone because the accuracy
Dovepress Keene et al
International Journal of Chronic Obstructive Pulmonary Disease 2019:14 submit your manuscript | www.dovepress.com
DovePress
2397
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
62
.6
.5
2.
11
 o
n 
28
-N
ov
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
of the ADO score may be affected by the inclusion of
screen-detected cases (which might not reﬂect usual
primary care populations). All analyses were undertaken
using STATA (StataCorp, College Station TX, USA).
Results
Out of 1894 cases in the cohort, two were younger than 40
years of age at baseline, 111 (5.9%) hadmissingmMRC score,
and 102 (5.4%) had missing FEV1% predicted values (22
(1.2%)) were missing both (Figure 1). Before imputing miss-
ing mMRC and FEV1% predicted, there were 1392 prevalent
and 309 incident cases (total 1701). The median observation
time was 3.02 years (minimum 1.77 and maximum 3.83
years). The average age was 68.4 years old and 651 (38.3%)
cases were female. The majority (79.5%) had mild-to-moder-
ate airﬂow obstruction (50.6% with GOLD stage II) and the
mean ADO score at baseline was 7.0 (SD 2.4). One hundred
and twenty-four (7.3%) deaths occurred within 3 years of
observation time, 116 (94%) of which occurred in the preva-
lent cases.
When compared to incident cases, prevalent cases
tended to have a worse baseline ADO score (older age,
more severe obstruction and worse breathlessness), lower
exercise capacity scores, more comorbidities, were more
likely to report a worse health-related quality of life score,
had more former smokers, and were more likely to report a
respiratory hospitalisation and at least one exacerbation in
the previous 12 months (Table 1).
Table 2 shows a comparison of characteristics of cases
according to whether or not they were alive within 3 years
of observation time. Those who died were older and had
more severe obstruction and dyspnoea (all P<0.001) which
resulted in a higher baseline ADO score (mean (SD) score
8.98 (2.14)) compared to those who remained alive (6.85
(2.39)). They were also less likely to be female, had poorer
exercise capacity, lower BMI, were more likely to have a
severe impact of COPD on health-related quality of life,
were more likely to have cardiovascular comorbidity, and
were more likely to report respiratory hospitalisation in the
12 months before baseline compared to those who
remained alive.
Figure 1 Patient (i.e. case) ﬂow chart from whole cohort to ADO validation sample.
Keene et al Dovepress
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Table 1 Comparison Of Baseline Characteristics Of Existing COPD Cases With Those Who Were Screen Detected (N=1701)
Prevalent Cases
N= 1392
Incident Cases
N= 309
Total
N= 1701
P-Valuea
Female – N (%) 528 (37.9) 123 (39.8) 651 (38.3) 0.540
Age in years – N (%)
40–49 46 (3.3) 18 (5.8) 64 (3.8) <0.001
50–59 167 (12.0) 65 (21.0) 232 (13.6)
60–69 536 (38.5) 119 (38.5) 655 (38.5)
70–79 469 (33.7) 106 (34.3) 575 (33.8)
80+ 174 (12.5) 1 (0.3) 175 (10.3)
GOLDb – N (%)
Mild (FEV1≥ 80% of normal) 317 (22.8) 175 (56.6) 492 (28.9) <0.001
Moderate (FEV1 ≥ 50 & <80% of normal) 734 (52.7) 127 (41.1) 861 (50.6)
Severe (FEV1 ≥ 30 & <50% of normal) 285 (20.5) 6 (1.9) 291 (17.1)
Very severe (FEV1 ≥ 0 & <30% of normal) 56 (4.0) 1 (0.3) 57 (3.4)
FEV1% predicted – mean(SD) 64.61 (20.3) 82.51 (16.6) 67.80 (20.8) <0.001
FEV1/FVC ratio – mean(SD) 0.55 (0.1) 0.63 (0.1) 0.57 (0.1) <0.001
mMRC dyspnoea – N (%)
0 233 (16.7) 106 (34.3) 339 (19.9) <0.001
1 301 (21.6) 96 (31.1) 397 (23.3)
2 307 (22.1) 62 (20.1) 369 (21.7)
3 244 (17.5) 22 (7.1) 266 (15.6)
4 307 (22.1) 23 (7.4) 330 (19.4)
Baseline ADO – mean(SD) 7.41 (2.4) 5.20 (1.9) <0.001
Baseline ADO groups – N (%)
0 to 5 265 (19.0) 170 (55.0) 435 (25.6) <0.001
6 to 7 471 (33.8) 101 (32.7) 572 (33.6)
8 to 9 392 (28.2) 37 (12.0) 429 (25.2)
10 to 14 264 (19.0) 1 (0.3) 265 (15.6)
White British/mixed British - N (%) 1,181 (84.8) 260 (84.1) 1441 (84.7) 0.757
Missing 98 (7.0) 23 (7.4)
IMDc deprivation score – N (%) 0.031
Most deprived – Quintile 1 290 (20.8) 49 (15.9) 339 (20.2)
Quintile 2 265 (19.0) 68 (22.0) 333 (19.8)
Quintile 3 249 (17.9) 71 (23.0) 320 (19.0)
Quintile 4 292 (21.0) 60 (19.4) 352 (20.9)
Least deprived – Quintile 5 288 (20.7) 50 (16.2) 338 (20.1)
Missing 8 (0.6) 11 (3.6)
Exercise capacityd – N (%)
Worst – 0 to 9 73 (5.2) 12 (3.9) 85 (6.1) <0.001
10 to 19 618 (44.4) 85 (27.5) 703 (50.0)
20 to 29 418 (30.0) 136 (44.0) 554 (39.4)
30 to 39 33 (2.4) 23 (7.4) 56 (4.0)
Best – 40 to 50 5 (0.4) 3 (1.0) 8 (0.6)
Missing 245 (17.6) 50 (16.18)
(Continued)
Dovepress Keene et al
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Figure 2 shows a Kaplan–Meier plot of the survival of
cases according to their ADO score at baseline. The sur-
vival curves are well separated which indicates good dis-
crimination. Cases with an ADO score of 10 or higher had
nearly 12 times the rate of death when compared to
patients with an ADO of 0 to 5.
Figure 3 shows AUC and calibration plots for prevalent
and incident cases. One thousand eight hundred and
ninety-two cases were available after imputing missing
mMRC and FEV1% predicted observations which added
30 more deaths (total equal to 154 deaths) within 3 years
of observation time (Figure 1). For 3-year mortality
Table 1 (Continued).
Prevalent Cases
N= 1392
Incident Cases
N= 309
Total
N= 1701
P-Valuea
BMI groups – N (%)
0–18.49 29 (2.1) 3 (1.0) 32 (2.0) 0.340
18.50–24.99 338 (24.3) 62 (20.1) 400 (24.8)
25.00–29.99 522 (37.5) 105 (34.0) 627 (38.9)
30.00+ 447 (32.1) 104 (34.0) 551 (34.2)
Missing 56 (4.0) 35 (11.3)
Smoking group – N (%)
Never smoker 130 (9.3) 43 (13.9) 173 (10.9) 0.005
Current smoker 369 (26.5) 95 (30.7) 464 (29.4)
Former smoker 795 (57.1) 149 (48.2) 944 (59.7)
Missing 98 (7.0) 22 (7.1)
HRQLe category – N (%)
Low impact – 0 to 9 139 (10.0) 71 (23.0) 210 (16.4) <0.001
10 to 19 374 (26.9) 105 (34.0) 479 (37.4)
20 to 29 381 (27.4) 51 (16.5) 432 (33.7)
Severe impact – 30 to 40 153 (11.0) 8 (2.6) 161 (12.6)
Missing 345 (24.8) 74 (24.0)
Exacerbation in last 12 months – N (%) 820 (58.9) 78 (25.2) 898 (54.5) <0.001
Missing 44 (3.2) 9 (2.9)
Cardiovascular disease history – N (%) 776 (55.8) 135 (43.7) 911 (53.6) <0.001
Any cancer – N (%) 173 (12.4) 39 (12.6) 212 (13.9) 0.737
Missing 162 (11.6) 16 (5.2)
Asthma – N (%) 565 (40.6) 84 (27.2) 649 (42.6) <0.001
Missing 155 (11.1) 21 (6.8)
Osteoporosis – N (%) 104 (7.8) 23 (7.4) 127 (8.8) 0.636
Missing 239 (17.2) 26 (8.4)
Depression – N (%) 255 (18.3) 68 (22.0) 323 (21.7) 0.360
Missing 190 (13.7) 22 (7.1)
Respiratory hospital admission in previous 12 months – N
(%)
82 (5.9) 3 (1.0) 85 (5.0) <0.001
Notes: Missing rows were added only for variables with missing data. Bold denotes statistical signiﬁcance. aP-values describe differences in characteristics between cohorts
without accounting for missing as a separate category. Chi-square test for categorical data and Student’s t-test for continuous data. bThe Global Initiative for Chronic
Obstructive Lung Disease (GOLD) categories of airﬂow limitation.cBased on the Index of Multiple Deprivation (IMD) 2010. Lower quintiles indicate more deprivation.
dAssessed using the sit-to-stand test.28 eHealth-related quality of life based on the COPD Assessment Test (CAT).
Abbreviations: FEV1, forced expiratory volume in one second; MRC, medical research council; HRQL, health-related quality of life.
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Table 2 Baseline Characteristics Of Cases (N=1701) By Whether Or Not They Died Within 3 Years Of Observation Time
Alive Within 3 Years Of
Observation Time (N=1577)
Dead Within 3 Years Of
Observation Time (N=124)
Total
(N= 1701)
P-Valuea
Female – N (%) 618 (39.2) 33 (26.6) 651 (38.3) 0.006
Age in years – N (%)
40–49 62 (3.9) 2 (1.6) 64 (3.8) <0.001
50–59 227 (14.4) 5 (4.0) 232 (13.6)
60–69 619 (39.3) 36 (29.0) 655 (38.5)
70–79 529 (33.5) 46 (37.1) 575 (33.8)
80+ 140 (8.9) 35 (28.2) 169 (9.9)
GOLDb stage – N (%)
Mild (FEV1≥ 80% of normal) 479 (30.4) 13 (10.5) 492 (28.9) <0.001
Moderate (FEV1 ≥ 50 & <80% of normal) 803 (50.9) 58 (46.8) 861 (50.6)
Severe (FEV1 ≥ 30 & <50% of normal) 252 (16.0) 39 (31.5) 291 (17.1)
Very severe (FEV1 ≥ 0 & <30% of normal) 43 (2.7) 14 (11.3) 57 (3.4)
FEV1% predicted – mean(SD) 69.0 (20.5) 55.2 (20.6) 68.0 (20.8) <0.001
FEV1/FVC ratio – mean(SD) 0.57 (0.13) 0.52 (0.15) 0.57 (0.13) <0.001
mMRC dyspnoea – N (%)
0 321 (20.4) 18 (14.5) 339 (19.9) <0.001
1 382 (24.2) 15 (12.1) 397 (23.3)
2 343 (21.8) 26 (21.0) 369 (21.7)
3 243 (15.4) 23 (18.6) 266 (15.6)
4 288 (18.3) 42 (33.9) 330 (19.4)
Baseline ADO – mean (SD) 6.85 (2.39) 8.98 (2.14) 7.01 (2.43) <0.001
Baseline ADO groups – N (%)
Low risk – 0 to 5 428 (27.1) 7 (5.7) 435 (25.6) <0.001
6 to 7 548 (34.8) 24 (19.4) 572 (33.6)
8 to 9 390 (24.7) 39 (31.5) 429 (25.2)
High risk – 10 to 14 211 (13.4) 54 (43.6) 265 (15.6)
White British/mixed British – N (%) 1331 (84.4) 110 (88.7) 1441 (84.7) 0.425
Missing 115 (7.3) 6 (4.8) 121 (7.1)
IMDc deprivation score – N (%) 0.406
Most deprived – Quintile 1 316 (20.0) 23 (18.6) 339 (19.9)
Quintile 2 302 (19.2) 31 (25.0) 333 (19.6)
Quintile 3 302 (19.2) 18 (14.5) 320 (18.8)
Quintile 4 324 (20.6) 28 (22.6) 352 (20.7)
Least deprived – Quintile 5 316 (20.0) 22 (17.7) 338 (19.9)
Missing 17 (1.1) 2 (1.6) 19 (1.1)
Exercise capacityd – N (%)
Worst – 0 to 9 75 (4.8) 10 (8.1) 85 (5.0) <0.001
10 to 19 644 (40.8) 59 (47.6) 703 (41.3)
20 to 29 536 (34.0) 18 (14.5) 554 (32.6)
30 to 39 55 (3.5) 1 (0.8) 56 (3.3)
Best – 40 to 50 8 (0.5) 0 8 (0.5)
Missing 259 (16.4) 36 (29.0) 295 (17.3)
(Continued)
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(N= 980), the ADO score was able to discriminate fairly
well between patients who died (N= 98) and those who
remained alive (AUC= 0.74; 95% CI: 0.69–0.79).
Discriminative ability remained consistent for 1-year
(N= 1892, 37 died; AUC=0.73; 95% CI: 0.66–0.80) and
2-year (N= 1,876, 93 died; AUC= 0.72; 95% CI: 0.67–
0.76) mortality. Calibration plots showed that the ADO
score accurately predicted 3-year mortality (calibration
slope= 0.95; 95% CI: 0.70 to 1.19) but over-prediction
was evident in those with higher predicted risks of mor-
tality at 1- (0.79; 95% CI: 0.45 to 1.13) and 2-year (0.79;
95% CI: 0.57 to 1.01) time periods. Predictions were also
too high (i.e. CITL< 0) at all time-periods; however, these
improved as the time periods lengthened. Re-introducing
cases that died within a period but with period end dates
after the 31 March 2016 only affected the 3-year mortality
Table 2 (Continued).
Alive Within 3 Years Of
Observation Time (N=1577)
Dead Within 3 Years Of
Observation Time (N=124)
Total
(N= 1701)
P-Valuea
BMI groups - N (%)
Underweight – 0–18.49 kg/m2 25 (1.6) 7 (5.7) 32 (1.9) 0.003
Normal – 18.50–24.99 kg/m2 365 (23.2) 35 (28.2) 400 (23.5)
Overweight – 25.00–29.99 kg/m2 583 (37.0) 44 (35.5) 627 (36.9)
Obese – 30.00 + kg/m2 520 (33.0) 31 (25.0) 551 (32.4)
Missing 84 (5.3) 7 (5.7) 91 (5.4)
Smoking group – N (%)
Never smoker 165 (10.5) 8 (6.5) 173 (10.2) 0.359
Current smoker 428 (27.1) 36 (29.0) 464 (27.3)
Former smoker 873 (55.4) 71 (57.3) 944 (55.5)
Missing 111 (7.0) 9 (7.3) 120 (7.1)
HRQLe category – N (%)
Low impact – 0 to 9 191 (12.1) 19 (15.3) 210 (12.4) 0.006
10 to 19 450 (28.5) 29 (23.4) 479 (28.2)
20 to 29 403 (25.6) 29 (23.4) 432 (25.4)
Severe impact – 30 to 40 138 (8.8) 23 (18.6) 161 (9.5)
Missing 395 (25.1) 24 (19.4) 419 (24.6)
Exacerbation in last 12 months – N (%) 830 (52.6) 68 (54.8) 898 (52.8) 0.619
Missing 49 (3.1) 4 (3.2) 53 (3.1)
Cardiovascular disease history – N (%) 823 (52.2) 88 (71.0) 911 (53.6) <0.001
Any cancer – N (%) 192 (12.2) 20 (16.1) 212 (12.5) 0.195
Missing 165 (10.5) 13 (10.5) 178 (10.5)
Asthma – N (%) 611 (38.7) 38 (30.7) 649 (38.2) 0.148
Missing 158 (10.0) 18 (14.5) 176 (10.4)
Osteoporosis – N (%) 119 (7.6) 8 (6.5) 127 (7.5) 0.689
Missing 244 (15.5) 21 (16.9) 265 (15.6)
Depression – N (%) 304 (19.3) 19 (15.3) 323 (19.0) 0.283
Missing 196 (12.4) 16 (12.9) 212 (12.5)
Respiratory hospital admission in previous
12 months – N (%)
66 (4.2) 19 (15.3) 85 (5.0) <0.001
Notes: Missing rows were added only for variables with missing data. Bold denotes statistical signiﬁcance. aP-values describe differences in characteristics between cohorts
without accounting for missing as a separate category. Chi-square test for categorical data and Student’s T-test for continuous data.b The Global Initiative for Chronic
Obstructive Lung Disease (GOLD) categories of airﬂow limitation. cBased on the Index of Multiple Deprivation (IMD) 2010. Lower quintiles indicate more deprivation.
dAssessed using the sit-to-stand test.28 eHealth-related quality of life based on the COPD Assessment Test (CAT).
Abbreviations: FEV1, forced expiratory volume in one second; MRC, medical research council; HRQL, health-related quality of life.
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outcome (N=1,036) and resulted in worse discimination
(AUC= 0.71; 95% CI: 0.67-0.76) and calibration (slope=
0.82; 95% CI: 0.62-1.02) (data not shown). An additional
sensitivity analysis with only prevalent patients showed
similar results for discriminative performance and calibra-
tion slopes (Supplementary Table 2). In the complete
cases, the calibration slope was decreased to 0.73 at 1-
year mortality when compared to the analysis that included
all cases. At 3-year mortality, calibration slope increased
to 1.08 while discrimination increased to 0.77.
Discussion
In this external validation study in a primary care COPD
population which included screen-detected and prevalent
cases, we found that the updated ADO score13 was
discriminatory with an AUC of 0.74 for predicting 3-
year mortality. Discrimination remained stable when
predicting 1- and 2-year mortality. However, we found
that the ADO score tended to over-predict mortality,
especially among the few patients with higher predicted
risks of mortality at 1- and 2-year time frames.
Our ﬁnding of an AUC of 0.74 is lower than the
development model (AUC= 0.85)13 but consistent with
estimates from two other studies that validated the ADO
score for predicting 3-year mortality, one in primary
care (AUC= 0.724, 95% CI: 0.719–0.730; mean
FEV1% predicted of participants: 59.5)
14 and the other
across multiple healthcare settings (AUC= 0.73, 95%
CI: 0.70–0.76; FEV1% predicted 65.9).
13 However, a
third study used a network meta-analysis to pool data
on patients across many healthcare settings and found
that the discriminative performance of the ADO score
was below 0.70 but still better than nine other prognos-
tic scores.15 Our ﬁndings are consistent with the results
of one primary care study for 1-year (AUC= 0.720; 95%
CI: 0.710–0.729) and 2-year (AUC= 0.725; 95% CI:
0.718–0.731) mortality,14 but slightly less accurate than
a second study for 2-year (AUC= 0.78; 95% CI: 0.71–
0.84)16 mortality since the upper CI of our 2-year AUC
estimate was slightly lower than 0.78.
Accurate calibration is particularly important for
evaluating prognostic models because predicted and
observed risk need to closely match for predictions to
be clinically useful.11 This is the ﬁrst study that reports
the calibration slope of the ADO score when predicting
3-year mortality. In addition to 3-year mortality, predic-
tions using shorter time frames are important because
clinicians rely on multicomponent prediction models to
identify patients nearing the end of life who may beneﬁt
from palliative care.29 No other studies have assessed
calibration for shorter time periods without adjusting the
model. We have shown that over-prediction was more
pronounced in patients with higher predicted risks of
mortality for these time periods. Thus, our ﬁndings
Figure 2 Kaplan–Meier plot of survival experience of patients by ADO score group at baseline. ADO score 0 to 5 used as the reference group (N= 1701).
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suggest that recalibration, for example, by using statis-
tical shrinkage techniques,30 is needed, in order for the
ADO score to better predict mortality over a shorter
time frame.
Our study overcomes several limitations found in pre-
vious validation studies. For example, we used recom-
mended statistical approaches for predicting mortality in
a validation study.26 Using a research dataset, such as the
Birmingham COPD cohort, had the advantage of more
accurate and higher quality measurements at prescribed
time points, particularly for spirometry. On the other
hand, the Birmingham COPD cohort is not completely
representative of all primary care patients with COPD.
Ethnic diversity was limited. Additionally, patients needed
to be mobile to take part in the cohort study and, therefore,
patients with more severe disease who were housebound
were more likely to be excluded. Since we used a ﬁxed
ratio (based on UK guideline recommendations) instead of
a lower limit of normal of FEV1/FVC to deﬁne COPD,
overdiagnosis may have occurred in older patients.31
Figure 3 Area-under-the-curve and calibration plots comparing observed and predicted mortality for incident and prevalent cases.
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However, the ADO score was developed in a population
where COPD was deﬁned using the ﬁxed ratio9 and using
the lower limit of normal could lead to underdiagnosis
compared to expert opinion.32 Furthermore, in a study of
24,207 US adults from 4 cohorts, COPD-related hospita-
lization and mortality were not signiﬁcantly different when
using the ﬁxed ratio of FEV1/FVC < 0.70 compared to the
lower limit of normal to deﬁne COPD.33 This indicates
that our results would not be very different if we had used
a lower limit of normal to deﬁne our cohort. We included
screen-detected COPD cases who, predictably, had very
few deaths. However, other studies have not included
screen-detected cases despite at least 50% of the COPD
population remaining undiagnosed worldwide.34 It is
important to assess the validity of prognostic indices to
predict mortality in this population to inform treatment
decisions. Finally, a very small number of deceased
patients may have had delayed death registration due to a
variety of reasons such as suspicious, unexpected, or acci-
dental deaths.35 In addition to the loss of power (i.e. fewer
deaths), if patients were considered alive when they were
truly dead, then this would result in weaker prognostic
accuracy.
Conclusion
It is well-known that prognostic scores are rarely used in
clinical practice for managing people with COPD, especially
in primary care.3 Although the ADO score is attractive
because of its accurate discriminative ability and ease of
measurement and calculation in a primary care setting recali-
bration is needed to improve risk prediction for shorter time
frames. Currently, when predicting 1- and 2-year mortality, the
ADO score may not be accurate in primary care populations
because over-prediction was evident, especially in those with
higher predicted risks ofmortality and peoplewith COPDmay
be given treatment that is not needed as a result.
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